AMGEN INC. $850,000,000 1.250% SENIOR NOTES DUE 2017 $1,400,000,000 2.200% SENIOR NOTES DUE 2019 $1,400,000,000 3.625% SENIOR NOTES DUE 2024 $600,000,000 SENIOR FLOATING RATE NOTES DUE 2017 $250,000,000 SENIOR FLOATING RATE NOTES DUE 2019 Underwriting...Underwriting Agreement • May 22nd, 2014 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $850,000,000 principal amount of the 1.250% Senior Notes due 2017 of the Company (the “2017 Notes”), an aggregate of $1,400,000,000 principal amount of the 2.200% Senior Notes due 2019 of the Company (the “2019 Notes”), an aggregate of $1,400,000,000 principal amount of the 3.625% Senior Notes due 2024 of the Company (the “2024 Notes”), an aggregate of $600,000,000 principal amount of the Senior Floating Rate Notes due 2017 of the Company (the “2017 Floating Notes”) and an aggregate of $250,000,000 principal amount of the Senior Floating Rate Notes due 2019 of the Company (the “2019 Floating Notes”, and together with the 2017 Notes, the 2019 Notes, the 2024 Notes and the 2017 Floating Notes, collectively, the “Securities”) to be issued pursuant to the provisions of an Indent
